Wall Street Zen Upgrades Minerva Neurosciences (NASDAQ:NERV) to Sell

Minerva Neurosciences (NASDAQ:NERV) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

A number of other research firms have also weighed in on NERV. Weiss Ratings restated a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, December 1st. HC Wainwright decreased their price objective on Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Minerva Neurosciences presently has a consensus rating of “Reduce” and a consensus target price of $4.00.

Minerva Neurosciences Trading Up 2.7%

Shares of NERV opened at $3.84 on Friday. The business’s fifty day moving average is $3.55 and its 200 day moving average is $2.51. Minerva Neurosciences has a 12-month low of $1.15 and a 12-month high of $12.46.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). On average, equities research analysts expect that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Apella Capital LLC grew its position in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,314 shares of the biopharmaceutical company’s stock after buying an additional 18,375 shares during the quarter. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.